The pharmaceutical firm's Q2 FY27 profit collapsed sequentially, overshadowing a 15% yearly revenue gain and raising questions about earnings stability.
Themis Medicare reported a 71% sequential drop in Q2 FY27 profit to ₹7.06 crore, even as revenue grew 15% year-on-year. The sharp decline highlights ongoing volatility, with non-operating income propping up the bottom line.
For Themis Medicare, the September quarter was a story of two diverging lines: a steady climb in revenue met a sharp fall in profit. The pharmaceutical company's top line grew, but its bottom line collapsed, revealing a core business still struggling for consistent footing.
Revenue rose 15.1% year-on-year to ₹89.74 crore, a modest 3.2% sequential increase. Profit, however, plunged 71.3% from the previous quarter to ₹7.06 crore. This dramatic swing turned a net profit margin of 28.3% in June into just 7.9% in September.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Revenue (₹ Cr), Q2 FY26 (Sep '25): 77.99
Revenue (₹ Cr), Q3 FY26 (Dec '25): 90.13
Revenue (₹ Cr), Q4 FY26 (Mar '26): 76.53
Revenue (₹ Cr), Q1 FY27 (Jun '26): 86.96
Revenue (₹ Cr), Q2 FY27 (Sep '26): 89.74
Profit (₹ Cr), Q2 FY26 (Sep '25): -3.62
Profit (₹ Cr), Q3 FY26 (Dec '25): 10.09
Profit (₹ Cr), Q4 FY26 (Mar '26): 8.88
Profit (₹ Cr), Q1 FY27 (Jun '26): 24.61
Profit (₹ Cr), Q2 FY27 (Sep '26): 7.06
Revenue (₹ Cr)
Revenue (₹ Cr), Q2 FY26 (Sep '25): 77.99
Revenue (₹ Cr), Q3 FY26 (Dec '25): 90.13
Revenue (₹ Cr), Q4 FY26 (Mar '26): 76.53
Revenue (₹ Cr), Q1 FY27 (Jun '26): 86.96
Revenue (₹ Cr), Q2 FY27 (Sep '26): 89.74
Profit (₹ Cr)
Profit (₹ Cr), Q2 FY26 (Sep '25): -3.62
Profit (₹ Cr), Q3 FY26 (Dec '25): 10.09
Profit (₹ Cr), Q4 FY26 (Mar '26): 8.88
Profit (₹ Cr), Q1 FY27 (Jun '26): 24.61
Profit (₹ Cr), Q2 FY27 (Sep '26): 7.06
Net Profit Margin
Net Profit Margin, Q2 FY26 (Sep '25): -4.6%
Net Profit Margin, Q3 FY26 (Dec '25): 11.2%
Net Profit Margin, Q4 FY26 (Mar '26): 11.6%
Net Profit Margin, Q1 FY27 (Jun '26): 28.3%
Net Profit Margin, Q2 FY27 (Sep '26): 7.9%
Metric
CurrentQ2 FY27 (Sep '26)
PreviousQ1 FY27 (Jun '26)
Revenue (₹ Cr)
89.74
86.96
Profit (₹ Cr)
7.06
24.61
Net Profit Margin
7.9%
28.3%
Why the profit vanished
The sequential profit collapse stems from the absence of a one-time gain that flattered the previous quarter. According to reports from AlphaTribe and others, Q1 FY27 included an exceptional profit of ₹93 crore from the sale of shares. Stripping that out, the core operating performance shows a company just returning to a fragile profitability.
This quarter's profit was itself propped up by non-core income. Other income of ₹4.14 crore accounted for over 50% of profit before tax, as noted by MarketsMojo. The reliance on such income underscores that the core pharmaceutical operations are generating thin returns.
A business split in recovery
Management commentary reported by Tulsian AI points to a split performance. The API business rebounded sharply, with revenue jumping 71% to ₹20 crore. The formulations segment held steady at ₹69 crore, with specific divisions like Critical Care and Ortho showing strong growth.
Live Chart
· THEMISMED
(BSE)
ISIN: INE083B01024
Yet, this recovery has not translated into strong cash generation. Reports Radar notes operating cash flow for the first half was a negative ₹57.44 crore, with substantial capital tied up in receivables and inventory. The balance sheet shows short-term borrowings of ₹56.19 crore against cash of ₹15.94 crore.
The market's verdict
Investors reacted to the earnings volatility with a sell-off. The stock tumbled 6.4% on the results day, closing at ₹95.03, according to MarketsMojo. The one-year return stands at -13.7%, reflecting deep skepticism.
This sentiment is echoed in a recent credit rating downgrade by CARE and a 'Strong Sell' rating from MarketsMojo. The valuation, with a P/E of 530 against an industry average of 40, prices in no margin for operational missteps.
Key Points
Profit fell 71% sequentially to ₹7.06 crore, erasing a one-time gain of ₹93 crore from the previous quarter.
Revenue grew 15% year-on-year, driven by a 71% rebound in the API business, while formulations remained stable.
The bottom line remains dependent on other income, which constituted over half of the pre-tax profit.
The stock fell sharply post-results, extending a one-year loss of nearly 14%, as volatility erodes investor confidence.
“
Hexa Perspective
The quarter confirms Themis Medicare is in a stabilization phase, not a sustained turnaround. The core business has returned to operating profit, but at a low-single-digit margin that offers little buffer. The heavy reliance on other income and weak cash flows are structural concerns that growth alone cannot fix.
Investors are weighing the genuine recovery in the API segment against erratic profitability and a leveraged balance sheet. For the stock to re-rate, the company needs to demonstrate that the current quarter's operating profit is repeatable and can grow without non-core support. Until then, the high valuation multiple looks like a bet on potential that remains largely unrealized.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Themis Medicare's Q2 FY27 results?
Themis Medicare reported Q2 FY27 revenue of ₹89.74 crore, a 15.1% increase year-on-year. Net profit was ₹7.06 crore, a significant turnaround from a loss of ₹3.62 crore in Q2 FY26, but it fell 71.3% compared to the previous quarter (Q1 FY27).
Why did Themis Medicare's Q2 FY27 profit fall 71% sequentially?
Themis Medicare's Q2 profit fell 71% from Q1 primarily because the previous quarter's profit of ₹24.61 crore was inflated by a one-time exceptional gain of ₹93 crore from the sale of shares, as reported by AlphaTribe. The Q2 profit reflects a return to a more normalized, lower level of earnings.
What was the contribution of other income to Themis Medicare's Q2 FY27 profit?
Other income contributed ₹4.14 crore to Themis Medicare's Q2 FY27 results. According to MarketsMojo, this amount constituted over 50% of the profit before tax, highlighting a significant dependency on non-operating income to support the bottom line.
How did Themis Medicare's formulations and API business segments perform in Q2 FY27?
In Q2 FY27, Themis Medicare's API business rebounded strongly, with revenue growing 71% year-on-year to ₹20 crore, as per management commentary reported by Tulsian AI. The formulations business revenue held steady at approximately ₹69 crore during the quarter.
What guidance did Themis Medicare management provide for FY27 after Q2 results?
Themis Medicare's management expressed optimism for the second half of FY27, as reported by Tulsian AI. They expect growth to be supported by operational efficiencies, field productivity, cost management, and a sustained recovery in the API business, with active engagement for new molecules overseas.
What is the status of Themis Medicare's working capital and cash flow in Q2 FY27?
Themis Medicare's working capital remains strained. For the first half of FY27, operating cash flow was negative ₹57.44 crore, as per Reports Radar. Substantial capital is tied up, with receivables at ₹154.95 crore and inventories rising to ₹102.92 crore since March 2026.
How did Themis Medicare's stock price react to the Q2 FY27 results announcement?
Themis Medicare's stock price fell 6.37% on November 16, 2026, closing at ₹95.03 following the Q2 FY27 results announcement, according to MarketsMojo. The reaction reflected investor concerns over the company's erratic profitability and the sharp sequential decline in net profit.
Did Themis Medicare's Q2 FY27 results beat or miss analyst estimates?
Available research snippets do not provide a clear consensus of analyst estimates to compare against Themis Medicare's Q2 FY27 results. The reported figures showed a profit turnaround year-on-year but a steep sequential decline.
Which brokerages have changed their rating or target price for Themis Medicare after Q2 FY27 results?
Research indicates no active brokerage recommendations or target price changes were widely reported post-results. However, MarketsMojo downgraded its rating on the stock to 'Strong Sell' on November 17, 2026, citing mixed financial and technical signals.
Themis Medicare Q2 profit drop
Themis Medicare's Q2 FY27 net profit dropped 71.3% quarter-on-quarter to ₹7.06 crore. This sharp decline was largely due to the absence of a one-time gain of ₹93 crore from share sales that had significantly boosted profit in the previous quarter (Q1 FY27).
Themis Medicare Q2 net profit
Themis Medicare's consolidated net profit for Q2 FY27 (September 2026 quarter) was ₹7.06 crore. This represents a turnaround from a net loss of ₹3.62 crore in the same quarter last year (Q2 FY26), but a steep fall from the ₹24.61 crore profit reported in the immediate preceding quarter.